Drug Profile

Aprepitant co-crystal - Oxilio

Alternative Names: LipAprep; OXL-001

Latest Information Update: 24 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oxilio
Class Antineoplastics; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Cancer

Most Recent Events

16 Mar 2026 OXL 001 is still in phase I trials for Cancer in the United Kingdom(TRx Bioscience pipeline, March 2026)
28 Dec 2025 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (PO, Capsule)
06 Nov 2022 Phase I trials in Cancer (In Volunteers) in United Kingdom (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com